Close monitoring and lifetime follow-up is optimal for patients with a history of melanoma

Seminars in Oncology

Volumn 30, Issue 3, 2003, Pages 369-374

  Christianson, David F ^b   Anderson, Clay M ^a  

^a UNIVERSITY OF MISSOURI   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; DIAGNOSTIC VALUE; FOLLOW UP; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; LABORATORY TEST; MELANOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT EDUCATION; PATIENT MONITORING; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RADIODIAGNOSIS; RECURRENT CANCER; REVIEW; SELF EXAMINATION; SKIN CANCER; SURVIVAL RATE; THORAX RADIOGRAPHY; UNITED STATES;

EID: 0038129922     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(03)00097-6     Document Type: Review

References (51)

1. Poo-Hwu WJ, Ariyan S, Lamb L, et al: Follow-up recommendations for patients, with American Joint Commission on Cancer stages I-III malignant melanoma. Cancer 86:2252-2258, 1999
2. Sober AJ, Tsu-yi C, Duvic M, et al: Guidelines of care for primary cutaneuos melanoma. J Am Acad Dermatol 45:579-586, 2001
3. Romero JB, Stefanato CM, Kopf AW, et al: Follow-up recommendations for patients for patients for patients with stage I malignant melanoma. J Dermatol Surg Oncol 20:175-178, 1994
4. McCarthy WH, Shaw HM, Thompson JF, et al: Time and frequency of recurrence of cutaneous stage I malignant melanoma with guidelines for follow-up study. Surg Gynecol Obstet 166:497-502, 1988
5. Reintgen DS, Cox C, Slingluff CL, et al: Recurrent malignant melanoma: The identification of prognostic indicators to predict survival. Ann Plast Surg 28:45-49, 1992
6. Ross MI: Staging evaluation and surveillance for melanoma patients in a fiscally restrictive medical environment. Surg Clin North Am .76:1423-1432, 1996
7. Kelly JW, Blois MS, Sagebiel RW; Frequency and duration of patient follow-up after treatment of a primary malignant melanoma. J Am Acad Dermatol 13:756-760, 1985
8. Brobeil A, Rapaport D, Wells K, et al: Multiple primary melanomas: Implications for screening and follow-up programs for melanoma. Ann Surg Oncol 4:19-23, 1997
9. Garbe C, Paul A, Kohler-Spath H, et al: Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: Recommendations for an effective follow-up strategy. J Clin Oncol 21:520-529, 2003
10. Rigel DS, Friedman RJ, Kopf AW: The incidence of malignant melanoma in the United States: Issues as we approach the 21st century. J Am Acad Dermatol 34:839-847, 1997
11. Jemal A, Thomas A, Murray T, et al: Cancer statistics, 2002. CA Cancer J Clin 52:23-47, 2002
12. Shumate CR, Urist MM, Maddox WA: Melanoma recurrence surveillance. Patient or physician based? Ann Surg 221:566-569, 1995
13. Weiss M, Loprinzi CL, Creagan ET, et al: Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA 274:1703-1705, 1995
14. Balch CM, Buzaid AC, Soong SJ, et al: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635-3648, 2001
15. Schmid-Wendtner M, Baumert J, Schmidt M, et al: Late metastases of cutaneous melanoma: An analysis of 31 patients. J Am Acad Dermatol 43:605-609, 2000
16. Shaw HM, Beattie CW, McCarthy WH, et al: Late relapse from cutaneous stage I malignant melanoma. Arch Surg 120:1155-1159, 1985
17. McEwan L, Smith JG, Matthews JP: Late recurrence of localized cutaneous melanoma: its influence on follow-up policy. Plast Reconstr Surg 86: 527-534, 1990
18. DiFronzo LA, Wanek LA, Morton DL: Earlier diagnosis of second primary melanoma confirms the benefits of patient education and routine postoperative follow-up. Cancer 91: 1520-1524, 2001
19. Difronzo LA, Wanek LA, Elashoff R, et al: Increased incidence of second primary melanoma in patients with a previous cutaneous melanoma. Ann Surg Oncol 6:705-711, 1999
20. Tafra L, Dale PS, Wanek LA, et al: Resection and adjuvant immunotherapy for melanoma metastatic to the lung and thorax. J Thorac Cardiovasc Surg 110:119-129, 1995
21. Petit T, Borel C, Rixe O, et al: Complete remission seven years after treatment for metastatic melanoma. Cancer 777:900-902, 1996
22. Ricaniadis N, Konstadoulakis MM, Walsh D, et al: Gastrointestinal metastases from malignant melanoma. Surg Oncol 4:105-111, 1995
23. Overett TK, Shiu MH: Surgical treatment of distant metastases: Indications and results. Cancer 56:1222-1230, 1985
24. Sasson HN, Poo WJ, Henderson-Bakas M, et al: Prolonged survival in patients with advanced melanoma treated with neoadjuvant chemotherapy followed by resection. Ann Plast Surg 37:286-292, 1996
25. Legha SS: Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with intefferon alpha and chemotherapy. Semin Oncol 24:S39-43, 1997
26. Legha SS, Ring S, Bedikian A, et al: Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon alpha. Ann Oncol 7:827-835, 1996
27. White RR, Stanley WE, Johnson JL, et al: Long-term survival in 2505 patients with melanoma with regional lymph node metastasis. Ann Surg 235:879-887, 2002
28. Kirkwood JM, Strawderman MH, Ernstoff MS, et al: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol 14:7-17, 1996
29. Soong S-J, Harrison RA, McCarthy WH, et al: Factors affecting survival following local, regional, or distant recurrence from localized melanoma. J Surg Oncol 67:228-233, 1998
30. Balch CM, Soong SJ, Gershenwald JE, et al: Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19:3622-3634, 2001
31. Greene FL, Page DL, Fleming ID, et al: (eds): AJCC (American Joint Committee on Cancer) Cancer Staging Manual (ed 6). New York, NY, Springer-Verlag, 2002, pp 211-212
32. Pearlman NW, Takach TJ, Robinson WA, et al: A case-control study of late recurrence of malignant melanoma. Am J Surg 164:458-461, 1992.
33. Tsao H, Cosimi AB, Sober AJ: Ultra-late recurrence (15 years or longer)of cutaneous melanoma. Cancer 79:2361-2370, 1997
34. Finck SJ, Giuliano AE, Morton DL: LDH and melanoma. Cancer 51:840-843, 1983
35. Balch CM, Houghton AN: Diagnosis of metastatic melanoma at distant sites, in Balch CM, Houghton AN, Milton GW, et al: Cutaneous Melanoma (ed 2). Philadelphia, PA, Lippincott; 1992, pp 439-467
36. Boni R, Huch Boni RA, Steinerty H, et al: Anti-melanoma monoclonal antibody 225.28s immunoscintigraphy in metastatic melanoma. Dermatology 191:119-123, 1995
37. Blend MJ, Hyun H, Patel B, et al: Radioimmunoscintigraphy in patients with early stage cutaneous malignant melanoma. J Nucl Med 37:252-257, 1996
38. Steinert HC, Huch Boni RA, Buck A, et al: Malignant melanoma: Staging with whole-body positron emission topography and (2-fL-18)-fluoro-2-deoxy-D-glucose. Radiology 195: 705-709, 1995
39. Boni R, Huch-Boni RA, Steinert H, et al: Early detection of melanoma metastasis using fludeoxyglucose F 18 positron emission topography. Arch Dermatol 132:875-876, 1996
40. Wagner JD, Schauwecker D, Hutchins G, et al: Initial assessment of positron emission topography for detection of nonpalpable regional lymphatic metastases in melanoma. J Surg Oncol 64:181-189, 1997
41. Hara H, Walsh N, Yamada K, et al: High plasma level of eurmelanin precursor, 6-hydroxy-5-methoxyindole-2-carboxylic acid as a prognostic marker for malignant melanoma. J Invest Dermatol 102:501-505, 1994
42. Yamada K, Walsh N, Hara H, et al: Measurement of eumelanin precursor metabolites in the urine as a new marker for melanoma metastases. Arch Dermatol 128:491-494, 1992
43. Faraj BA, Camp VM, Murray DR, et al: Plasma L-dopa in the diagnosis of malignant melanoma. Clin Chem 32:159-161, 1986
44. Kuvshinoff BW, Kurtz C, Coit DG: Computed tomography in evaluation of patients with Stage III melanoma. Ann Surg Oncol 4:252-258, 1997
45. Ariyan S, Poo WJ, Bolognia JL, et al: Multiple primary melanomas: Data and significance. Plast Reconstr Surg 96: 1384-1389, 1995
46. Koh HK, Caruso A, Gage I, et al: Evaluationof melanoma/skin cancer screening in Massachusetti. Preliminary results. Cancer 65:375-379, 1990
47. Grin CM, Kopfn AW, Welkovich B, et al: Accuracy in the clinical diagnosis of malignant melanoma. Arch Dermatol 126:763-766, 1990
48. Ramsay DL, Fox AB: The ability of primary care physicians to recognize the common dermatoses. Arch Dermatol 117:620-622, 1981
49. Cassileth BR, Clark WH, Luek ET, et al: How well do physicians recognize melanoma and other problem lesions? J. Am Acad Dermatol 14:555-560, 1986
50. Kang S, Barnhill RL, Minn MC, et al: Multiple primary cutaneous melanomas. Cancer 70:1911-1916, 1992
51. Reider-Growasser I, Merimsky, O, Karminsky N, et al: Computed tomography features of cerebral spread of malignant melanoma. Am J Clin Oncol 19:49-53, 1996